Amgen Reveals P-III (MINT) Study Data of Uplizna (Inebilizumab-cdon) to Treat Generalized Myasthenia Gravis (gMG)
Shots:
- Amgen has reported P-III (MINT) trial data on Uplizna vs PBO in adults (N=238) with AChR+ gMG (n=190) or MuSK+ gMG (n=48), followed for 52 & 28wks., respectively; sBLA under FDA’s priority review for IgG4-RD (PDUFA: Apr 3, 2025), with regulatory filings expected to end by H1’25
- Pts received an initial loading dose of Uplizna followed by 2 doses per year, while pts on corticosteroids began tapering at Wk. 4, reducing to prednisone (5 mg/day) by Wk. 24. Eligible pts could also opt for 3yr. OLE study
- Trial showed durable efficacy in AChR+ pts, with 72.3% vs 45.2% achieving ≥3-point MG-ADL improvement & 69.2% vs 41.8% showing ≥3-point QMG improvement by 52wks; data to be presented at AAN 2025
Ref: Amgen | Image: Amgen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
